NeoGenomics Beats Natera Cancer Test Patent Infringement Lawsuit

NeoGenomics Laboratory Inc. defeated Natera Inc.'s lawsuit accusing it of infringing two patents with its cell-free DNA cancer-detection test.

Natera’s US Patent Nos. 11,519,035 and 11,530,454 are invalid because they are directed at a natural phenomenon and don’t describe an inventive concept, according to an opinion issued Thursday in the US District Court for the Middle District of North Carolina.

The patents’ steps are simply a “logical combination” of “standard, well-known techniques” using off-the-shelf products, Chief District Judge Catherine C. Eagles wrote in granting NeoGenomics summary judgment.

Eagles used the two-step test set out by the Supreme Court’s 2014 decision ...